相关实验视频

Updated: Jul 24, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

在功能延迟的皮肤冠状动脉干预患者中,最佳的降脂疗法是通过皮肤冠状动脉干预

Takuro Abe¹, Kensuke Shimazaki¹, Tetsu Moriyama¹

¹Department of Cardiology, Nishiarai Heart Center Hospital, Tokyo, Japan.

Scientific reports

|July 5, 2023

概括

对于中级冠状动脉狭窄和延迟皮肤冠状动脉干预 (PCI) 的患者来说,严格的低密度脂蛋白胆固醇 (LDL-C) 管理至关重要. 降低LDL-C显著降低了FFR在0.81-0.85.85之间的人的主要不良心血管事件.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学

背景情况:

推迟穿皮冠状动脉干预 (PCI) 对于功能不显著的冠状动脉狭窄 (部分流量储备 (FFR) >0.80) 与积极的长期结果有关.
管理低密度脂蛋白胆固醇 (LDL-C) 的"最好最低"策略是一种公认的非血管塑性方法,用于改善PCI患者的临床结果.

研究的目的:

调查中期冠状动脉狭窄症患者的最佳LDL-C管理策略,其中基于FFR值推迟PCI.
为了确定LDL-C水平是否会在这个特定的患者群体中影响重大心血管和脑血管不良事件 (MACCE).

主要方法:

一项观察性研究涉及273名单一目标血管和推迟PCI (FFR>0.80) 的患者.
患者按FFR (0.81-0.85对比>0.85) 和LDL-C水平 (<100 mg/dL对比≥100 mg/dL) 分层.
主要终点是MACCE,包括死亡,心肌梗塞,中风,心力衰竭住院治疗和无计划的再血管.

主要成果:

与FFR>0.85 (p=0.003) 患者相比,FFR0.81-0.85的患者表现出明显更高的MACCE率.
在FFR0.81-0.85组中,较低的LDL-C (<100 mg/dL) 与显著较低的MACCE率 (p=0.006) 有关.
在FFR>0.85 (p=0.84) 的患者中,LDL-C组之间没有观察到MACCE率的显著差异.

结论:

不控制的LDL-C水平与由于FFR值为0.81-0.85.85的延迟PCI患者的MACCE风险增加相关.
这种高危子组需要积极的LDL-C降低疗法来缓解不良心血管结果.

更多相关视频

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

相关概念视频

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...